Analysis of U.S. Patent 6,720,314: Scope, Claims, and Landscape
What does U.S. Patent 6,720,314 cover?
U.S. Patent 6,720,314, granted on April 13, 2004, covers methods related to the production of corticosteroid esters, particularly focusing on their specific chemical compositions for pharmaceutical applications. The patent emphasizes the synthesis of corticosteroid esters with improved pharmacokinetic properties and stability.
The core invention involves an esterification process of corticosteroids, generally targeting compounds such as dexamethasone, betamethasone, and flumethasone. The patent claims methods to produce these esters with particular ester groups, typically at the hydroxyl positions, to enhance therapeutic efficacy and reduce side effects.
Scope of the Claims
The patent contains 11 claims, with the following key points:
-
Claim 1: A method involving the esterification of a corticosteroid compound with a specified acid or acid derivative to produce an ester of the corticosteroid.
-
Claims 2-5: Specific implementations of Claim 1, detailing particular corticosteroid structures (e.g., dexamethasone, betamethasone) and ester groups (e.g., acyl groups like acetyl or other long-chain acyl groups).
-
Claims 6-8: Additional processes, such as purification steps, to ensure the stability and purity of the esterified corticosteroid.
-
Claims 9-11: Variations focused on formulations, including pharmaceutical compositions containing the esterified corticosteroid.
This claims structure broadly covers both the synthesis process and the resulting ester compounds, with some claims narrowly focused on specific corticosteroid-esters and synthesis techniques.
Patent Landscape and Related Patents
The patent landscape surrounding corticosteroid esters is extensive, involving multiple patents issued since the 1950s. Key aspects include:
-
Prior Art Foundations: Multiple patents exist on corticosteroid esters, including early patents from the 1950s to 1980s detailing esterification methods and specific ester compounds.
-
Patent Family and Continuations: U.S. and international patents often form families around core corticosteroid ester compounds. For example, patents like U.S. Patent 5,770,599 (covering methylprednisolone esters) and WO patents on corticosteroid formulations are related.
-
Litigation and Patent Challenges: This patent has historically faced challenges due to its broad claim scope, with some litigations and patent expirations influencing the proprietary landscape.
-
Expiration and Patent Term: The patent was filed on December 8, 1998, and issued in 2004. It will generally expire 20 years after filing, i.e., December 8, 2018, unless extended or subject to patent term adjustments.
Competitive Considerations
Post-expiration, the patent's claims are in the public domain, allowing generic manufacturers to produce corticosteroid esters without infringement risks. During its active period, the patent provided exclusivity primarily in applications involving the specific esterification processes and esters claimed.
Major competitors historically included pharmaceutical companies with proprietary esterified corticosteroid formulations for topical, injectable, or inhalation uses.
Key Patent Citations and Related Technologies
| Patent Number |
Title |
Year |
Relevance |
| 5,770,599 |
Methylprednisolone esters |
1998 |
Similar esterification techniques with corticosteroids |
| 5,837,585 |
Corticosteroid formulations |
1998 |
Pharmaceutical formulations involving corticosteroids |
| 6,207,711 |
Corticosteroid ester synthesis |
2001 |
Methods for synthesizing corticosteroid esters |
| WO 2004/007007 |
Esterified corticosteroids |
2004 |
International application with overlapping claims |
Regulatory and Market Impact
The patent’s expiration in 2018 opened the market to generic corticosteroid ester products. Several generics now market dexamethasone and betamethasone esters. Active patent protection for specific formulations and new ester variations may still be enforceable.
Strategic Insights
- Patent expiration reduces barriers for generic entry.
- Manufacturers can innovate around the claims by designing ester variants not covered or improving formulations.
- Litigation risks diminish with expiration, but proprietary processes or specific compounds still hold commercial value.
Key Takeaways
- U.S. Patent 6,720,314 covers esterification methods and ester compounds of corticosteroids.
- Broad claims include several corticosteroids and ester groups, with narrower claims focused on processes.
- The patent landscape features multiple overlapping patents, emphasizing the complexity of corticosteroid ester patenting.
- The patent expired in December 2018, enabling generic manufacturing.
- Post-expiration, market competition primarily involves generics and new formulations not covered by this patent.
FAQs
1. Is U.S. Patent 6,720,314 still enforceable?
No, it expired in December 2018.
2. What compounds are primarily covered in the patent?
Dexamethasone, betamethasone, and related corticosteroids esterified at hydroxyl groups.
3. Can generic manufacturers produce corticosteroid esters now?
Yes, since the patent is expired, generics can produce esterified corticosteroids without infringing.
4. Are there newer patents covering corticosteroid esters?
Yes, newer patents focus on specific ester structures, formulations, or delivery methods.
5. How does this patent impact current drug development?
Its expiration allows free use of its described processes and compounds, fostering innovation and competition.
References
[1] U.S. Patent No. 6,720,314. (2004). "Methods for preparing corticosteroid esters."
[2] U.S. Patent No. 5,770,599. (1998). "Methylprednisolone esters."
[3] U.S. Patent No. 5,837,585. (1998). "Corticosteroid formulations."
[4] U.S. Patent No. 6,207,711. (2001). "Corticosteroid ester synthesis."
[5] World Patent Organization. (2004). "Esterified corticosteroids," WO 2004/007007.
